0

Global Myelofibrosis Therapeutics Market 2018-2022

  • Published: Dec 2018
  • Pages: 103
  • SKU: IRTNTR23859
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The global myelofibrosis therapeutics market size will grow by USD 639.26 million during 2018-2022. This industry research report provides a detailed analysis of the market based on the type of treatment (drug therapy, blood transfusion, HSCT, and androgen therapy), and geography (the Americas, APAC, and EMEA). The report analyzes the market’s competitive landscape and offers information on several myelofibrosis therapeutics manufacturers including Bristol-Myers Squibb, CELGENE, Incyte, and Novartis.

Below are some of the key findings from this myelofibrosis therapeutics market analysis report

Global Myelofibrosis Therapeutics Market

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global myelofibrosis therapeutics industry outlook

The need for disease-modifying drugs for myelofibrosis is driving its therapeutics market. The only FDA approved drug therapy for myelofibrosis is JAKAVI/JAKAFI, but it has dose-related side effects that tend to halt the disease progression to acute leukemia. Other drugs and steroids prescribed by a physician are the off-label ones, which merely focus on prolonging the survival along with the disease. Hematopoietic stem cell transplantation (HSCT) therapy is also having disadvantages regarding the unavailability of matching donors and other therapies only reduce the anemic side-effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can help in eradicating the disease completely, which makes the need for disease-modifying drugs for myelofibrosis important, driving the myelofibrosis therapeutics market growth at a CAGR of more than 7% during the forecast period.

Top myelofibrosis therapeutics companies covered in this market research report

The global myelofibrosis therapeutics market is extremely concentrated. The market is in the initial stage of the growth phase, and the competition is expected to become less intense by the end of the forecast period. To help clients improve their revenue shares in the market, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this myelofibrosis therapeutics market analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.

The report offers a detailed analysis of several leading companies, including:

  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

Myelofibrosis therapeutics market segmentation based on the type of treatment

  • Drug therapy
  • Blood transfusion
  • HSCT
  • Androgen therapy

Drug therapy held the largest share of the global myelofibrosis therapeutics market in 2017. The market share of this segment will increase, and it will continue to dominate the market throughout the next five years.

Myelofibrosis therapeutics market segmentation based on region

  • The Americas
  • APAC
  • EMEA

The Americas accounted for the largest myelofibrosis therapeutics market share in 2017. This region will witness an increase in its market share and remain the market leader for the next five years.

Key highlights of the global myelofibrosis therapeutics market for the forecast years 2018-2022:

  • CAGR of the market during the forecast period 2018-2022
  • Detailed information on factors that will accelerate the growth of the myelofibrosis therapeutics market during the next five years
  • Precise estimation of the global myelofibrosis therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the myelofibrosis therapeutics industry across the Americas, APAC, and EMEA
  • A thorough analysis of the market’s competitive landscape and detailed information on several vendors
  • Comprehensive details on factors that will challenge the growth of myelofibrosis therapeutics companies 

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

 

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT

  • Segmentation by type of treatment
  • Comparison by type of treatment
  • Drug therapy – Market size and forecast 2017-2022
  • Blood transfusion – Market size and forecast 2017-2022
  • HSCT – Market size and forecast 2017-2022
  • Androgen Therapy – Market size and forecast 2017-2022
  • Market opportunity by type of treatment

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas – Market size and forecast 2017-2022
  • EMEA – Market size and forecast 2017-2022
  • APAC – Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • HSCT is the only curative option for myelofibrosis
  • High off-label prescription including hydroxyurea, Immunomodulators, and steroids

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

PART 16: APPENDIX

  • List of abbreviations

 

 

  

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted
Technavio

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Technavio
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>